INTRODUCTION
============

Recent large randomized controlled studies have demonstrated the usefulness of multi-parametric magnetic resonance imaging (mpMRI) for prostate cancer (PCa) detection \[[@B1][@B2]\]. Target biopsy based on mpMRI has a higher detection rate for clinically significant PCa (csPCa) than conventional random systematic biopsy used as a standard tool so far \[[@B1]\]. In the past few years, the use of mpMRI has made tremendous changes in the diagnosis of PCa.

Prostate Imaging--Reporting and Data System (PI-RADS) version 2 is the most widely used evaluation criteria for magnetic resonance imaging (MRI) findings of PCa \[[@B3]\]. Following PI-RADS version 2 guideline, T2-weighted imaging (T2WI), apparent diffusion coefficient (ADC) maps, high b-value diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) imaging are used. T2WI is a key image for transitional zone lesion, while ADC map using various b-value DWI is the most valuable technique for characterizing peripheral zone lesion. Compared to PI-RADS version 1 guideline, the need for DCE is minimized in PI-RADS version 2. DCE images are useful only for peripheral zone lesion with PI-RADS 3 to distinguish PI-RADS 4 from 3. Biopsy is even necessary in both scores. However, burdens of mpMRI including additional cost, acquisition time, and side effects of contrast agent are still present. For these reasons, a simple and standardized MRI protocol is needed to replace mpMRI including DCE. Recently, bi-parametric MRI (bpMRI) including T2WI and DWI has a similar diagnostic accuracy and does not use contrast agent \[[@B4][@B5]\].

High b-value DWI has been emphasized in PI-RADS version 2 guideline. The signal intensity (SI) of the normal prostate gland is often not suppressed in DWI, even when b-value=1,000 s/mm^2^ (b1000) are used \[[@B6]\]. Higher b-value DWI would be more advantageous in detecting relatively small diffusion changes such as those between the normal prostate parenchyma and foci of PCa, thus yielding greater tissue diffusivity and less T2 shine-through effect \[[@B7]\]. Unfortunately, there is still no consensus regarding the optimal b-value as a high b-value DWI. Several small-scale studies have determined the accuracy of PCa detection using various b-value DWI \[[@B8][@B9][@B10][@B11][@B12]\]. They found that b-values in the range of 1,500 to 2,500 s/mm^2^ were optimal for PCa detection \[[@B12]\]. Although higher b-value DWI clearly shows the lesion from the background, it has lower sensitivity for detecting PCa.

With recent development of MRI technology, most institutions have been able to use ultra-high b-value (b≥1,800 s/mm^2^) DWI. Therefore, creating a simple and widely available standard MRI protocol using ultra-high b-value DWI is possible. The objective of this study was to determine the benefit of using ultra-high b-value (b=1,800 s/mm^2^, b1800) DWI and to compare this bpMRI protocol with high b-value (b=1,000 s/mm^2^, b1000) DWI to detect csPCa.

MATERIALS AND METHODS
=====================

1. Ethics statement
-------------------

This retrospective, single-center study was approved by Pusan National University Yangsan Hospital Institutional Review Board (IRB) (No. 05-2016-007). Data analysis was waived review and consent by the IRB Board, as all data was being analyzed retrospectively, after de-identification.

2. Subject and study methods
----------------------------

From January 2014 to July 2018, 408 men who underwent prostate biopsy and bpMRI before biopsy at Pusan National University Yangsan Hospital were enrolled. Two urologists (SWP and DHL) who had 8 and 5 years of experience in prostate MRI, respectively, performed systematic biopsy in all men and cognitive target biopsy for visible lesion (PI-RADS 3--5). A genitourinary pathologist reviewed and described all biopsy cores. For each positive biopsy core of PCa, Gleason score and cancer core length were reported. A csPCa was defined as the presence of a single biopsy core indicating disease of Gleason score 3+4 (Gleason sum of 7) or greater \[[@B2]\].

In our institute, all patients underwent 3.0 T MRI (InteraAchieva 3.0 T; Phillips Medical System, Best, Netherlands) on an instrument equipped with a phased-array coil (six channels). For bpMRI, axial T2WI for anatomical evaluation and DWI scans were acquired within 4 and 8 minutes, respectively. Using three b-values (50, 400, and 1,000), diffusion restriction was quantified as ADC map. The b1800 DWIs were obtained by additional sequence. We divided the MRI protocol and compared the results of the radiologic and pathologic results in each protocol. MRI protocol A (n=133) included T2WI, ADC, and b1000 DWI, while MRI protocol B (n=275) included T2WI, ADC, b1000, and b1800 DWI. MRI protocol A was performed until December 2015. Subsequent patients were evaluated using MRI protocol B since January 2016. Without any clinical information, one reader (SWP) retrospectively reviewed all images for confirmation of PI-RADS score.

In men who were evaluated by MRI protocol B, SIs of visible lesions (PI-RADS 3--5) and adjacent background were evaluated manually by tracing a region of interest within an identified lesion on b1000 and b1800 DWIs corresponding to the location of the index lesion on the ADC map \[[@B12]\]. The SI ratio of the lesion/background was then calculated for each patient.

All patients were prepared with local gel anesthetics using a BK ultrasound scanner (BK Medical, Peabody, MA, USA), an endfire transducer, a needle guide, and an 18G 25 cm biopsy needle. After the operator reviewed the MRI, any suspicious lesions on MRI (PI-RADS 3--5 lesion) were visually matched and registered on the corresponding axial transrectal ultrasonography image based on zonal anatomy. All target biopsy cores were marked and kept in separate bottles according to the location of the suspicious lesion on MRI. After target biopsy, systematic biopsy cores were collected from 12 prostatic regions and marked separately. Patients without suspicious lesions (PI-RADS 1--2) on MRI underwent systematic biopsy only.

Demographic, pathologic, and radiologic results of patients were compared between MRI protocol A and MRI protocol B groups using chi-square test and t-test for categorical and continuous variables, respectively. PCa detection rates and proportions of csPCa according to MRI protocol and PI-RADS score were compared. The odds ratio of b1000 and b1800 SI ratio (lesion/background) for csPCa detection in PI-RADS 3--5 lesion with MRI protocol B were evaluated. For binary logistic regression test, the cutoff of the SI ratio was 1.3 and 1.5 for b1000 and b1800 DWI, respectively. The distribution of SIs are shown using boxplots. All comparing analyses were performed using PASW ver. 18.0 (IBM Corp., Armonk, NY, USA). Statistical significance was considered at p≤0.05. Using MedCalc ver. 18.6 (MedCalc Software, Ostend, Belgium), the receiver operating characteristic curve for csPCa detection was analyzed. For each MRI protocol, specificity, sensitivity, positive predictive value, and negative predictive value were also evaluated.

RESULTS
=======

The median age, prostate-specific antigen, and prostate volume of the overall cohort were 64 years old (interquartile range \[IQR\]: 58--71 years old), 6.8 ng/mL (IQR: 5.0--9.5 ng/mL), and 36.2 mL (IQR: 27--50 mL), respectively. [Table 1](#T1){ref-type="table"} shows no significant demographic characteristics difference in both groups. Among 164 men confirmed with PCa, 102 had csPCa. Although the detection rate of overall PCa in each group was not significantly different (38.3% *vs.* 41.1%, p=0.667), the csPCa detection rate using MRI protocol B (27.6%) was higher (p=0.048) than that using MRI protocol A (19.5%).

Proportions of PI-RADS 1--2/3/4/5 in MRI protocol A and B cohorts were 19.5%/57.9%/15.8%/6.8% and 21.1%/48.7%/22.2%/8.0%, respectively ([Table 1](#T1){ref-type="table"}). [Fig. 1](#F1){ref-type="fig"} shows csPCa detection rates using MRI protocol B in men with PI-RADS 4/5 lesions were 63.9%/100%, it is significantly higher than those of MRI protocol A (38.1%/66.7%) (p=0.004/0.001, respectively). However, csPCa detection rates in men with PI-RADS 3 lesion is not different in both group.

Areas under the curve of PI-RADS score for scPCa detection were 0.705 and 0.885 in MRI protocol A and B cohorts, respectively. In MRI protocol A/B cohort, sensitivity, specificity, positive predictive value, and negative predictive values were 0.538/0.803, 0.850/0.889, 0.467/0.735, and 0.883/0.922, respectively, for PI-RADS 1--3 *vs.* 4--5 lesions. In MRI protocol A/B cohort, those were 0.885/0.987, 0.215/0.286, 0.215/0.346, and 0.885/0.983, respectively, for PI-RADS 1--2 *vs.* 3--5 lesions. The cutoff of PI-RADS 1--3 *vs.* 4--5 lesions using MRI protocol B was the most accurate among variable conditions.

[Fig. 2](#F2){ref-type="fig"} shows the lesion distribution and background SI in PI-RADS 3--5 lesions. Except for PI-RADS 4--5 lesions in b1800 DWI, visible lesion and background SI values severely overlapped with each DWI. The mean SI ratios (lesion/background) were 1.36 and 1.60 in b1000 and b1800 DWI, respectively (p\<0.001). The odds ratio of the SI ratio for predicting csPCa in b1000 and b1800 DWI were 3.2 (95% confidence interval \[CI\], 1.7--6.0; p\<0.001) and 5.1 (95% CI, 3.2--9.0; p\<0.001), respectively.

DISCUSSION
==========

The most important result of our study was that bpMRI including b1800 DWI increased the csPCa detection rate from 19.5% to 27.8%. Higher detection rate of csPCa in PI-RADS 4--5 lesions is the most important cause of this increase. Comparing SI ratio (lesion/background) of b1000 DWI, higher those of b1800 in PI-RADS 4--5 make it easier to identify lesions.

Standardization of MRI protocol is crucial for broad application of MRI. PI-RADS version 2 guideline is based on T2W, DWI, and DCE \[[@B3]\]. DWIs are used to calculate ADC maps with mono-exponential fitting of DWIs acquired at various b-values (≤1,000 s/mm^2^). High b-value (≥1,400 s/mm^2^) DWI should be obtained by direct acquisition or computed from the source DWI. However, ultra-high b-value (≥1,800 s/mm^2^) DWI is not mandatory. Several studies have suggested the benefit of b1800 or higher b-value DWI for csPCa detection \[[@B8][@B9][@B10][@B11][@B12]\]. In the past, it was infeasible to measure ultra-high b-value DWIs with an acceptable image quality. Long echo times were required, causing significant loss of signal-to-noise ratio. To reduce these effects, various b-values DWI with an acceptable signal-to-noise ratio were generally obtained and virtual high b-values DWI were mathematically extrapolated \[[@B13]\].

A quality-assured MRI protocol and experienced reader are essential for constant csPCa detection rate according to PI-RADS score. In the PROMIS study, csPCa detection rates with PI-RADS 3, 4, and 5 lesions were 21%, 58%, and 81%, respectively \[[@B1]\]. Similarly, those in the PRICISION study were 12%, 60%, and 83%, respectively \[[@B2]\]. Results of this study in the overall cohort were 12%, 56%, and 90%, respectively, consistent with results of two past large studies. However, results in MRI protocol A cohort were relatively disappointing, with detection rates of 12%, 38%, and 67%, respectively. Those with MRI protocol B were 10%, 64%, and 100%, respectively. The csPCa detection rates in MRI protocol B were higher than those in MRI protocol A for PI-RADS 4 and 5 lesions. Compared with b1000 DWI, b1800 DWI could discriminate lesion from adjacent background for PI-RADS 4--5 lesions more clearly. However, lesion and background SI values in both MRI protocol cohort severely overlapped in PI-RADS 3 and, even in PI-RADS 4--5 lesions in b1000 DWI ([Fig. 2](#F2){ref-type="fig"}). In csPCa patients, the SI ratio (lesion/background) of b1800 DWI had higher odds ratio than that of b1000 DWI (5.1 *vs.* 3.2). Therefore, more accurate localization of csPCa in PI-RADS 4--5 lesions could lead to higher csPCa detection rates.

In addition to accuracy, cost-effectiveness is more important in the application of MRI to biopsy-naïve patients. To date, most guidelines recommend that MRI should be used when the first biopsy is negative \[[@B14]\]. However, in recent PROMIS and Pahwa et al\'s study \[[@B15]\], the use of MRI in the first session biopsy improves the accuracy of csPCa detection, and the cost-effectiveness is also advantageous, considering prostate specific antigen follow-up, re-biopsy, and additional costs because of delayed diagnosis \[[@B16]\].

We did not compare the cost-effectiveness of mpMRI and bpMRI. The cost of mpMRI in our institution was approximately 600 US dollars, and about 45 minutes of imaging time was required to obtain all necessary images. Our bpMRI protocol consisted of only two sequences: axial T2WI for anatomical evaluation and DWI. These sequences were acquired within 4 minutes and 8 minutes, respectively. The cost for bpMRI procedure was reduced to 300 US dollars. As we described in the previous studies, the overall detection rates of csPCa were not different between the mpMRI and bpMRI \[[@B17]\]. In addition, several studies used simple bpMRI for cost-effectiveness \[[@B15][@B17][@B18][@B19]\]. bpMRI avoids additional cost, acquisition time, and side effects caused by contrast media. Cheikh et al \[[@B4]\] reported that DCE did not have any significant differences compared with T2WI. In their study, DCE was significantly less specific (83.5% *vs.* 89.7%, p\<0.002) than T2WI. Moreover, while DCE was more sensitive (52.4% *vs.* 32.1%), the difference was not significant (p=0.09). Delongchamps et al \[[@B5]\] also reported that DCE did not increase the accuracy, compared with DWI, for PCa detection in either the prostate peripheral or transitional zone. Therefore, DCE only plays a role as the minor sequence when peripheral zone cancer is equivocally suspected.

Several inevitable limitations exist in this retrospective study. First, accuracies of MRI protocols A and B were analyzed with different populations. However, baseline characteristics including age, prostate-specific antigen, or prostate volume were not significantly different between the two MRI protocols. Second, PI-RADS version 2 guideline was updated during the study period. Therefore, we added b1800 DWI since 2016. Third, the learning curve could be a limitation because MRI protocols A and B were performed in different periods. However, we already used mpMRI for over 100 cases for target biopsy before this study period. Forth, we did not analyzed according to zonal anatomy, peripheral and transitional zone lesion. The optimal sequence is different for detection of csPCa in peripheral and transitional zone \[[@B3]\].

CONCLUSIONS
===========

Adding b1800 DWI to bpMRI protocol improved the diagnostic accuracy and detection rate of csPCa. For PI-RADS 4 and 5 lesions, the csPCa detection rates using bpMRI with b1800 DWI were higher than those in bpMRI with b1000 DWI. A higher SI ratio of lesion/background in b1800 DWI makes it possible to distinguish suspected lesions more clearly. Among men with PI-RADS score 4--5 lesions, over 70% were diagnosed with csPCa after prostate biopsy in the present study.
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![Detection rate of overall and clinically significant cancer according to Prostate Imaging--Reporting and Data System (PI-RADS) score in each magnetic resonance imaging protocol. ^a^Magnetic resonance imaging (MRI) protocol A included T2-weighted imaging (T2WI), apparent diffusion coefficient (ADC), and b1000 diffusion-weighted imaging (DWI), ^b^MRI protocol B included T2WI, ADC, b1000, and b1800 DWI.](wjmh-38-370-g001){#F1}

![Signal intensity (SI) of Prostate Imaging--Reporting and Data System (PI-RADS) 4--5 lesion was higher than SI of background in b-value 1,800 s/mm^2^ diffusion-weighted imaging (DWI). Severe overlap of values with SI was observed under other conditions.](wjmh-38-370-g002){#F2}

###### Demographic, radiological, and pathological characteristics according to magnetic resonance protocol

![](wjmh-38-370-i001)

  Variable                                 Protocol A^a^ (n=133)   Protocol B^b^ (n=275)   p-value
  ---------------------------------------- ----------------------- ----------------------- ---------
  Age (y)                                  64 (58--71)             64 (59--70)             0.307
  PSA (ng/mL)                              6.6 (4.9--8.8)          6.8 (5.0--10.1)         0.234
  Prostate volume (mL)                     35.0 (27.0--48.0)       37.7 (27.7--51.3)       0.408
  PSAD (ng/mL/mL)                          0.17 (0.13--0.29)       0.19 (0.12--0.29)       0.470
  Previous negative biopsy                 17 (12.8)               31 (11.3)               0.743
  Positive DRE                             47 (35.3)               89 (32.4)               0.698
  Total biopsy core                        15 (14--15)             15 (13--15)             0.248
  Target biopsy core                       3 (2--3)                3 (2--3)                0.925
  PI-RADS score                                                                            0.348
   3                                       77 (57.9)               134 (48.7)              
   4                                       21 (15.8)               61 (22.2)               
   5                                       9 (6.8)                 22 (8.0)                
  Overall prostate cancer                  51 (38.3)               113 (41.1)              0.667
  Clinically significant prostate cancer   26 (19.5)               76 (27.6)               0.048

Values are presented as median (interquartile range) or number (%).

PSA: prostate specific antigen, PSAD: prostate specific antigen density, DRE: digital rectal examination, PI-RADS: Prostate Imaging--Reporting and Data System.

^a^Magnetic resonance imaging (MRI) protocol A included T2-weighted imaging (T2WI), apparent diffusion coefficient (ADC), and b1000 diffusion-weighted imaging (DWI), ^b^MRI protocol B included T2WI, ADC, b1000, and b1800 DWI.
